Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June
June 06 2018 - 5:01AM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage
biotechnology company focused on the development of novel cancer
therapeutics, announced today Susan M. Molineaux, Ph.D, founder,
CEO and President and Keith Orford, M.D., Ph.D., Senior Vice
President of Clinical Development will participate in the following
two investment conferences in June:
The Jefferies 2018 Healthcare Conference at the Grand Hyatt in
New York City. Calithera will present at the conference today, June
6, 2018 at 8:00 a.m. Eastern time. A live webcast of this
presentation will be accessible via the media and investors page of
www.calithera.com. An archived replay of the webcast will be
available on the Company’s website for 30 days following the
conference.
The JMP Securities 2018 Life Sciences Conference at the St.Regis
in New York City. Calithera will participate in a panel discussion
on June 20, 2018 at 3:30 p.m. Eastern time.
About Calithera
Calithera is a clinical-stage biopharmaceutical company focused
on fighting cancer by discovering, developing, and commercializing
novel small molecule drugs that target tumor and immune cell
metabolism. Calithera is headquartered in South San Francisco,
California. For more information about Calithera, please visit
www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. The
product candidates that Calithera develops may not progress through
clinical development or receive required regulatory approvals
within expected timelines or at all. In addition, clinical trials
may not confirm any safety, potency or other product
characteristics described or assumed in this press release. Such
product candidates may not be beneficial to patients or
successfully commercialized. The failure to meet expectations with
respect to any of the foregoing matters may have a negative effect
on Calithera's stock price. Additional information concerning these
and other risk factors affecting Calithera's business can be found
in Calithera's most recent Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission, and other periodic filings
with the Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, Calithera disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
SOURCE: Calithera Biosciences, Incorporated
CONTACT:
Jennifer McNealey
ir@Calithera.com
650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024